Meeting
2016 Genitourinary Cancers Symposium
Neoadjuvant gemcitabine and carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy: A propensity score-matched analysis.
Authors
Takuya Koie
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Takuya Koie , Chikara Ohyama , Atsushi Imai , Shingo Hatakeyama , Takahiro Yoneyama , Yasuhiro Hashimoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 375)
DOI
10.1200/jco.2016.34.2_suppl.375
Abstract #
375
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy.
First Author: Shingo Hatakeyama
Poster
2024 ASCO Genitourinary Cancers Symposium
Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.
First Author: Yu Zeng
Poster
2023 ASCO Genitourinary Cancers Symposium
Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience.
First Author: Mayumi Forster
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
First Author: Ali Raza Khaki